The Risks, Costs, and Benefits of Possible Future Global Policies for Managing Polioviruses

Kids Risk Project, Harvard School of Public Health, 677 Huntington Ave, Third Floor, Boston, MA 02115, USA.
American Journal of Public Health (Impact Factor: 4.55). 08/2008; 98(7):1322-30. DOI: 10.2105/AJPH.2007.122192
Source: PubMed


We assessed the costs, risks, and benefits of possible future major policy decisions on vaccination, surveillance, response plans, and containment following global eradication of wild polioviruses.
We developed a decision analytic model to estimate the incremental cost-effectiveness ratios and net benefits of risk management options for polio for the 20-year period and stratified the world according to income level to capture important variability between nations.
For low-, lower-middle-, and upper-middle-income groups currently using oral poliovirus vaccine (OPV), we found that after successful eradication of wild polioviruses, OPV cessation would save both costs and lives when compared with continued use of OPV without supplemental immunization activities. We found cost-effectiveness ratios for switching from OPV to inactivated poliovirus vaccine to be higher (i.e., less desirable) than other health investment opportunities, depending on the actual inactivated poliovirus vaccine costs and assumptions about whether supplemental immunization activities with OPV would continue.
Eradication promises billions of dollars of net benefits, although global health policy leaders face difficult choices about future policies. Until successful eradication and coordination of posteradication policies, health authorities should continue routine polio vaccination and supplemental immunization activities.

Download full-text


Available from: Kimberly M Thompson, Apr 02, 2014
  • Source
    • "The Global Polio Eradication Initiative to date has reduced the annual burden of disease to fewer than 2000 cases of paralysis annually. In the developed nations, vaccine-associated polio is a more significant risk than natural imported infection, which in turn affects the cost–benefit considerations of vaccinating the population and the type of vaccine chosen (Thompson et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Vaccine development has played a hugely important role in combating infectious disease. Despite this success, there is still a great need for new vaccines and these are emerging far more slowly than we would wish. Despite the massive expansion in understanding of immune responses to infection, research is often hindered by a lack of understanding of the immune responses required specifically for protection, or by a lack of approved adjuvants and delivery systems to induce the required responses. In addition, the financial commitment required to license new vaccines is significant, and the more lucrative markets are often not those with the greatest need. In this review, we discuss many of the hurdles that new vaccines must overcome in order to reduce morbidity and mortality, and some of the initiatives that are being attempted to supply new vaccines to those that need them most.
    Preview · Article · Feb 2012 · Journal of Medical Microbiology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Infectious diseases are major contributors to the global burden of illness in terms of morbidity and mortality. Over the past few decades and in spite of earlier achievements in controlling few major infections, new challenges are undermining the global effort by the emergence and re-emergence of new pathogens, development of resistance in microbes and their vectors and the intentional use of microorganisms to cause harm. Furthermore, policies and tools for prevention and control are not keeping pace with expanded threats. Objectives: In order to appreciate the global challenge of infectious disease, this course has three objectives. First, it explores the biological and epidemiological fundamentals of human-microbes interaction including dynamics of transmission of infectious agents in human populations. This knowledge will then be used to examine the impact of different disease control strategies on interruption of transmission and reduction of burden of illness. The second objective is to examine several model infectious diseases as case studies for policies impacting their endemicity, burden of illness and efforts to prevent and limit their spread. These will include examples of viral infections such as Poliomyelitis and HIV/AIDS, bacterial pathogens such as pneumococci and tuberculosis and parasites such as malaria and neglected tropical diseases. The third objective is to examine the role of several international organizations, partnerships and philanthropy in developing policies and implementing programs for control of global infection. Readings: The purpose of the required reading list is to expose students to a selective range of studies and reviews used to explore the challenge of global infection and strategies for their control. The course is intended to facilitate students appreciation of biological and epidemiological findings and how they are used to develop and implement control policies for infectious disease. Emphasis will be placed on critical examination of the impact of these plans. The format of the class will combine lecture presentation and
    Preview · Article ·
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Global prevention and control of infectious diseases requires significant investment of financial and human resources and well-functioning leadership and management structures. The reality of competing demands for limited resources leads to trade-offs and questions about the relative value of specific investments. Developing investment cases can help to provide stakeholders with information about the benefits, costs, and risks associated with available options, including examination of social, political, governance, and ethical issues. We describe the process of developing investment cases for globally coordinated management of action plans for measles and rubella as tools for enabling the implementation of the Global Vaccine Action Plan (GVAP). We focus on considerations related to the timing of efforts to achieve measles and rubella goals independently and within the context of ongoing polio eradication efforts, other immunization priorities, and other efforts to control communicable diseases or child survival initiatives. Our analysis suggests that the interactions between the availability and sustainability of financial support, sufficient supplies of vaccines, capacity of vaccine delivery systems, and commitments at all levels will impact the feasibility and timing of achieving national, regional, and global goals. The timing of investments and achievements will determine the net financial and health benefits obtained. The methodology, framing, and assumptions used to characterize net benefits and uncertainties in the investment cases will impact estimates and perceptions about the value of prevention achieved overall by the GVAP. We suggest that appropriately valuing the benefits of investments of measles and rubella prevention will require the use of integrated dynamic disease, economic, risk, and decision analytic models in combination with consideration of qualitative factors, and that synthesizing information in the form of investment cases may help stakeholders manage expectations as they chart the course ahead and navigate the decade of vaccines.
    Full-text · Article · Apr 2013 · Vaccine
Show more